Flurbiprofen analogs and methods of use in treating cancer
Flurbiprofen analog compounds having an amino acid derivatized at the flurbiprofen alkanoic acid carboxyl group and terminating at an ester or amide group are effective in inhibiting cancer cells in vitro and inhibiting the growth of cancers in viva. The compounds and pharmaceutical compositions containing them are particularly useful for the treatment of lung, pancreatic and head and neck cancers.
1. A compound having the structural formula:
including pharmaceutically acceptable salts thereof, where
R 1 is selected from H or a 1-4 carbon alkyl,
R 2 is selected from F, Cl, and Br and may include two or more R 2 substitutions on the ring,
R 3 is selected from H, F, Cl and Br, and may include two or more non-H substitutions on the ring,
—NH—CH(R 4 )—C(O)— is a hydrophobic amino acid residue, and
R 5 is 1-(3-Aminopropyl)-4-methylpiperazine (Amp) or 4-Amino-2,2,6,6-tetramethylpiperidine (Atmp).
2. The compound of claim 1 , wherein —NH—CH(R 4 )—C(O)— is selected from the group consisting of (4-Phenylphenyl)alanine) (Bip), 3,3-Diphenylalanine (Dip), O-(2,6-dicholorbenzyl)-tyrosine (OC2Y), 3-(2-Naphthyl)alanine (2Nal), 3-Benzothienylalanine (Bta), β-Cyclohexylalanine (βCha), 3-Pyridylalanine (3 Pal), β-(p-Biphenylyl)-β-alanine (βBpa), 4-Trifluoromethylphenylalanine (F3MF), luorophenylalanine(PFF), and Melphalane (MEL).
3. The compound of claim 1 , wherein R 2 is a single meta-position F.
4. The compound of claim 1 , wherein R 3 is H.
5. The compound of claim 1 , wherein R 1 is CH 3 .
6. The compound of claim 1 , having the structure
wherein —NH—CH(R 4 )—C(O)— is selected from the group consisting of (4-Phenylphenyl)alanine) (Bip), 3,3-Diphenylalanine (Dip), O-(2,6-dicholorbenzyl)-tyrosine (OC2Y), 3-(2-Naphthyl)alanine (2Nal), 3-Benzothienylalanine (Bta), β-Cyclohexylalanine (βCha), 3-Pyridylalanine (3 Pal), β-(p-Biphenylyl)-β-alanine (βBpa), 4-Trifluoromethylphenylalanine (F3MF), luorophenylalanine (PFF), and Melphalane (MEL).
7. The compound of claim 1 , which is a pure R or S enantiomer or an RS racemic mixture at the chiral position * and a pure L or pure D enantiomer or an LD racemic mixture at the chiral position #.
8. The compound of claim 1 , which is a pure S enantiomer at the chiral position * and a pure S enantiomer at the chiral position #.
9. A pharmaceutical composition containing the compound of claim 1 in a pharmaceutically acceptable medium suitable for oral or parenteral administration.
10. A method of treating a solid tumor in a mammalian subject wherein the cancer is pancreatic or lung cancer, comprising administering to the subject a therapeutically effective amount of compound of claim 1 , and repeating said administration at intervals of at least twice per week for a period of at least four weeks.
11. The method of claim 10 , wherein said compound is administered on a daily basis at a daily dose between 1 and 25 mg/kg body weight.
12. The method of claim 10 , wherein said compound is administered orally, intraperitoneally, intravenously, or intra-nasally or by inhalation.
13. The method of claim 10 , which further includes administering to the subject a second cancer therapy regimen selected from radiotherapy and one or more other chemotherapeutic compounds.
14. The method of claim 13 , wherein administering the compound is effective to potentiate the effect of the second cancer therapy regimen.
15. The method of claim 10 , wherein the compound administered is the compound of claim 9 .
16. The method of claim 10 , wherein said administering includes administering the compound at a daily dose between 1 and 25 mg/kg body weight of the compound over a period of at least five weeks.
17. A compound having a structural formula selected from the group consisting of:
and pharmaceutically acceptable salts thereof.